Stock listing
RNXT Stock Price, News, Filings & Events — Renovorx, Inc.
Selected listing: RNXT · NASDAQ · USD · US
This page tracks Renovorx, Inc.'s RNXT:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following RNXT:NASDAQ. RNXT:NASDAQ is the stock-level entry point for investors researching Renovorx, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Renovorx, Inc. is a public company traded under the ticker RNXT on the American market. With a market capitalization of approximately $38.98 million, Renovorx focuses on innovative solutions in its industry. The company aims to create value for its stakeholders through strategic initiatives and operational excellence.

- Ticker
- RNXT:NASDAQ
- Asset type
- Stock
- Market cap
- $59.6M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
Renovorx, Inc. RNXT:NASDAQ stock context
This page tracks Renovorx, Inc.'s RNXT:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following RNXT:NASDAQ. RNXT:NASDAQ is the stock-level entry point for investors researching Renovorx, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Renovorx, Inc. is a public company traded under the ticker RNXT on the American market. With a market capitalization of approximately $38.98 million, Renovorx focuses on innovative solutions in its industry. The company aims to create value for its stakeholders through strategic initiatives and operational excellence.
Latest news from Renovorx, Inc.
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Dr...
August 25, 2026
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
August 21, 2026
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therape...
August 20, 2026
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
August 11, 2026
RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, Augu...
August 4, 2026
Research Renovorx, Inc.
Renovorx, Inc. investor report
Review AI stock analysis and investor report context for RNXT:NASDAQ.
Renovorx, Inc. company profile
View the public company page for Renovorx, Inc. on 6ix.
Renovorx, Inc. news
Read company news and market updates connected to Renovorx, Inc..
Renovorx, Inc. investor events
Find investor webinars, events, and replay context for Renovorx, Inc..